Motif Bio plc

Stock Exchange: XLON; XNAS Ticker: MTFB HQ: London, United Kingdom Employees: 7 Signatory to Davos Decl: Yes Signatory to Industry Roadmap: No
Performance by research area
How Motif Bio plc was evaluated
1 2.1 2.2 2.3 3 4
R&D A
1 2 3
M&P B
1 2 3 4 5 6 7
AA&S C
Applicable indicator Not applicable

Performance

Motif Bio is a biopharmaceutical company, selected for having a pipeline that targets priority pathogens. It was evaluated in the area of Research & Development only. Motif Bio invested USD 35 million in antibiotic drug development in 2016. Its performance in the Benchmark is low compared with other biopharmaceutical companies in scope. It has two projects in its antimicrobial R&D pipeline, both targeting priority pathogens. During the period of analysis, the company did not engage in public-private partnerships but conducted R&D in-house and/or with private-sector partners to develop its candidate compounds. Motif Bio has one R&D project in late-stage clinical development, and reports that it has both an access and stewardship commitment in place for this candidate.

Operations

Motif Bio is a biopharmaceutical company which specialises in developing novel antibiotics against infections caused by multidrug-resistant bacteria. The company’s most advanced antibiotic drug candidate, iclaprim, is active against gram-positive bacteria. It is currently being developed for the treatment of acute bacterial skin and skin structure infections and hospital-acquired pneumonia, including infections caused by methicillin-resistant S. aureus (MRSA) and multidrug-resistant S. pneumoniae. The compound was acquired from Nuprim Inc. in 2015 following the merger of the two companies. In 2017, it was granted ‘orphan drug’ status by the FDA (for developing a drug or biological product to treat a rare disease or condition) for treating S. aureus lung infections in patients with cystic fibrosis. The company aims to collaborate with universities and other pharmaceutical companies to expand its pipeline of antibiotics against gram-positive and gram-negative bacteria. Motif Bio is a member of the BEAM alliance, a group of biopharmaceutical companies addressing the regulatory and commercial environments in Europe regarding R&D, approval and market viability of products combating antimicrobial resistance. Motif Bio has no products on the market. In 2016, the company raised USD 25 million from UK and US investors though a NASDAQ IPO.

Antimicrobial Portfolio

Motif Bio does not have any products on the market.

Opportunities

Plan ahead for access and stewardship during R&D. Motif Bio has stated a commitment to ensure access and stewardship provisions are in place for its antibiotic candidate (iclaprim) in late-stage clinical development. It can ensure that these provisions are applied and implemented accordingly.

A. Research & Development

Indicators scored on
  • 1
  • 2.1
  • 2.2
  • 2.3
  • 3
  • 4
Antimicrobial pipeline
2 projects, 2 target priority pathogens

A.2.1-2.2 Two candidates targeting priority pathogens. 

Biopharmaceutical companies in scope were selected based on their pipelines that target priority bacteria. Motif Bio invested USD 35 million in antibiotic drug development in 2016. The company has two projects in its antimicrobial R&D pipeline targeting priority pathogens, both in development for the treatment of gram-positive bacterial infections. The company’s most advanced antibiotic candidate is iclaprim, an antibiotic designed to be effective against bacteria that are resistant to other antibiotics, including trimethoprim, a commonly used antibiotic with the same mechanism of action. Iclaprim is an antibiotic of the dihydrofolate reductase (DHFR) inhibitor class that is active against methicillin-resistant S. aureus (MRSA). Iclaprim is currently in Phase III clinical development and is being developed for acute bacterial skin and skin structure infections (ABSSSI) and hospital-acquired bacterial pneumonia (HABP). Motif Bio is also developing another antibiotic in the preclinical stage, targeting MRSA.

A.3 No public-private partnerships reported during the period of analysis. 

Motif Bio conducts R&D in-house and/or with private-sector partners. During the period of analysis, it did not participate in public-private partnerships, or in partnerships with non-profit organisations, for antimicrobial R&D. After the period of analysis, the company announced in vitro testing of iclaprim’s activity against various strains of Burkholderia, Stenotrophomonas and Achromobacter, in partnership with the Cystic Fibrosis Foundation.

A.4 Access and stewardship commitments for iclaprim. 

Motif Bio reports that it has both an access and a stewardship commitment in place for its antibiotic candidate in late-stage development. The company commits to filing iclaprim for registration based on public health needs and disease prevalence. It also commits to ensuring access to its product in low- and middle-income countries, with pricing strategies that take affordability into account. For this indicator, countries in scope are 106 low- and middle-income countries where access to medicine is likely limited.

Pipeline targeting priority pathogens

Enlarge

B. Manufacturing & Production

As a biopharmaceutical company with no products on the market, Motif Bio was not eligible for this Research Area.

C. Appropriate Access & Stewardship

As a biopharmaceutical company with no products on the market, Motif Bio was not eligible for this Research Area.



Got a question?

Learn more

View our detailed overview of each company’s performance